David T. Curiel, M.D., Ph.D.
Director
Division of Human Gene Therapy

502 Biomedical Research Building II
901 19th Street South
Birmingham, AL 35294-2172, USA

curiel@uab.edu
Phone: (205) 934-8627
Fax: (205) 975-7476

Research Interests

My current research interest relates to the development of vector systems for the achievement of targeted, cell-specific gene delivery. This central field mandate is being addressed via the development of adenoviral vector systems, which embody genetic capsid modifications allowing tropism modification. In addition, the parallel study of the biologic dictates of adenovirus entry is currently being endeavored. Tropism modification via genetic capsid modification is based upon rigorous biologic characterization of vector/target cell interaction. Further, structure/function analysis of the viral capsid protein provides the basis of engineered alterations for tropism modification. At the cellular level, study of native viral receptors involves characterizing the dictates of tropism in vitro and in vivo with respect to described Ad receptors. In addition, cloning of cryptic receptors is being endeavored to identify novel Ad receptors.

Select List of Publications

  1. Ugai H, Borovjagin AV, Le LP, Wang M, Curiel DT. Thermostability/Infectivity Defect Caused by Deletion of the Core Protein V Gene in Human Adenovirus Type 5 is Rescued by Thermo-selectable Mutations in the Core Protein X Precursor. J Mol Biol. 2007 Mar 2;366(4):1142-60. Epub 2006 Dec 6. PMID: 17208253

  2. Stoff-Khalili MA, Rivera AA, Stoff A, Mathis JM, Rocconi RP, Matthews QL, Numnum MT, Herrmann I, Dall P, Eckhoff DE, Douglas JT, Siegal GP, Zhu ZB, Curiel DT. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer. Int J Cancer. 2007 Feb 15;120(4):935-41. PMID: 17131341

  3. Pereboeva L, Komarova S, Roth J, Ponnazhagan S, Curiel DT. Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.Gene Ther. 2007 Jan 25; [Epub ahead of print]. PMID: 17251987

  4. Stoff A, Rivera AA, Mathis JM, Moore ST, Banerjee NS, Everts M, Espinosa-de-Los-Monteros A, Novak Z, Vasconez LO, Broker TR, Richter DF, Feldman D, Siegal GP, Stoff-Khalili MA, Curiel DT. Effect of adenoviral mediated overexpression of fibromodulin on human dermal fibroblasts and scar formation in full-thickness incisional wounds. J Mol Med. 2007 Jan 12; [Epub ahead of print] PMID: 17219096

  5. Matthews QL, Sibley DA, Wu H, Li J, Stoff-Khalili MA, Waehler R, Mathis JM, Curiel DT. Genetic Incorporation of a Herpes Simplex Virus Type 1 Thymidine Kinase and Firefly Luciferase Fusion into the Adenovirus Protein IX for Functional Display on the Virion. Mol Imaging. 2006 Oct-Dec;5(4)510-9. PMID: 17150163

  6. Le LP, Li J, Ternovoi VV, Siegal GP, Curiel DT. Fluorescently tagged canine adenovirus via modification with protein IX-enhanced green fluorescent protein. J Gen Virol. 2005 Dec;86(Pt 12):3201-8.

  7. Le LP, Rivera AA, Glasgow JN, Ternovoi VV, Wu H, Wang M, Smith BF, Siegal GP, Curiel DT. Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells. Gene Ther. 2005 Nov 17;

  8. Breidenbach M, Rein DT, Schondorf T, Khan KN, Herrmann I, Schmidt T, Reynolds PN, Vlodavsky I, Haviv YS, Curiel DT. A new targeting approach for breast cancer gene therapy using the Heparanase promoter. Cancer Lett. 2005 Nov 2

  9. Mahasreshti PJ, Kataram M, Wu H, Yalavarthy LP, Carey D, Dent P, Fisher PB, Chada S, Alvarez RD, Haisma HJ, Curiel DT. Ovarian cancer targeted adenoviral-mediated mda-7/IL-24 gene therapy. Gynecol Oncol. 2005 Oct 10

  10. Izumi M, Kawakami Y, Glasgow JN, Belousova N, Everts M, Kim-Park S, Yamamoto S, Wang M, Le LP, Reynolds PN, Curiel DT. In vivo analysis of a genetically modified adenoviral vector targeted to human CD40 using a novel transient transgenic model. J Gene Med. 2005 Sep 19

  11. Hedley SJ, Auf der Maur A, Hohn S, Escher D, Barberis A, Glasgow JN, Douglas JT, Korokhov N, Curiel DT. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther. 2005 Aug 18

  12. Stoff-Khalili MA, Rivera AA, Glasgow JN, Le LP, Stoff A, Everts M, Tsuruta Y, Kawakami Y, Bauerschmitz GJ, Mathis JM, Pereboeva L, Seigal GP, Dall P, Curiel DT. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy. Gene Ther. 2005 Dec;12(23):1696-1706

  13. Li J, Le L, Sibley DA, Mathis JM, Curiel DT. Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion. Virology. 2005 Aug 1;338(2):247-58

  14. Zhu ZB, Makhija SK, Lu B, Wang M, Rivera AA, Kim-Park S, Ulasov IV, Zhou F, Alvarez RD, Siegal GP, Curiel DT. Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo. Int J Oncol. 2005 Jul;27(1):237-46

  15. Everts M, Kim-Park SA, Preuss MA, Passineau MJ, Glasgow JN, Pereboev AV, Mahasreshti PJ, Grizzle WE, Reynolds PN, Curiel DT. Selective induction of tumor-associated antigens in murine pulmonary vasculature using double-targeted adenoviral vectors. Gene Ther. 2005 Jul;12(13):1042-8

  16. Korokhov N, de Gruijl TD, Aldrich WA, Triozzi PL, Banerjee PT, Gillies SD, Curiel TJ, Douglas JT, Scheper RJ, Curiel DT. High Efficiency Transduction of Dendritic Cells by Adenoviral Vectors Targeted To DC-SIGN. Cancer Biol Ther. 2005 Mar;4(3):289-94. Epub 2005 Mar 20

  17. Wu H, Han T, Belousova N, Krasnykh V, Kashentseva E, Dmitriev I, Kataram M, Mahasreshti PJ, Curiel DT. Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol. 2005 Mar;79(6):3382-90

  18. Stoff-Khalili MA, Dall P, Curiel DT. From gene therapy to virotherapy for ovarian cancer. Minerva Ginecol. 2004 Dec;56(6):503-14. Review

  19. Rein DT, Breidenbach M, Kirby TO, Han T, Siegal GP, Bauerschmitz GJ, Wang M, Nettelbeck DM, Tsuruta Y, Yamamoto M, Dall P, Hemminki A, Curiel DT. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res. 2005 Feb 1;11(3):1327-35

  20. Kirby TO, Rivera A, Rein D, Wang M, Ulasov I, Breidenbach M, Kataram M, Contreras JL, Krumdieck C, Yamamoto M, Rots MG, Haisma HJ, Alvarez RD, Mahasreshti PJ, Curiel DT. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res. 2004 Dec 15;10(24):8697-703.

  21. Ternovoi VV, Le LP, Belousova N, Smith BF, Siegal GP, Curiel DT. Productive replication of human adenovirus type 5 in canine cells. J Virol. 2005 Jan;79(2):1308-11

  22. Breidenbach M, Rein DT, Everts M, Glasgow JN, Wang M, Passineau MJ, Alvarez RD, Korokhov N, Curiel DT. Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther. 2005 Jan;12(2):187-93

  23. Volk AL, Rivera AA, Page GP, Salazar-Gonzalez JF, Nettelbeck DM, Matthews QL, Curiel DT. Employment of microarray analysis to characterize biologic differences associated with tropism-modified adenoviral vectors: utilization of non-native cellular entry pathways. Cancer Gene Ther. 2005 Feb;12(2):162-74

  24. Contreras JL, Xie D, Mays J, Smyth CA, Eckstein C, Rahemtulla FG, Young CJ, Anthony Thompson J, Bilbao G, Curiel DT, Eckhoff DE. A novel approach to xenotransplantation combining surface engineering and genetic modification of isolated adult porcine islets. Surgery. 2004 Sep;136(3):537-47

  25. Pereboeva L, Komarova S, Mahasreshti PJ, Curiel DT. Fiber-mosaic adenovirus as a novel approach to design genetically modified adenoviral vectors. Virus Res. 2004 Sep 15;105(1):35-46

  26. Le LP, Everts M, Dmitriev IP, Davydova JG, Yamamoto M, Curiel DT. Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol Imaging. 2004 Apr;3(2):105-16


Biosketch

Current Positions

01/00 - Present Director, Division of Human Gene Therapy, UAB, Birmingham, Alabama
06/99 - present Professor of Gene Therapy, Free University of Amsterdam, Amsterdam, The Netherlands
07/97 - Present Jeanne and Ann Griffin Chair for Women's Cancer Research, UAB, Birmingham, Alabama
10/96 - Present Professor, Departments of Medicine, Microbiology, Gynecologic Oncology, Pathology and Hematology/Oncology; Senior Scientist, Comprehensive Cancer Center; Center for AIDS Research; UAB Arthritis and Musculoskeletal Diseases Center; and Gregory Fleming Cystic Fibrosis Center, University of Alabama at Birmingham
07/93 - present Director, Gene Therapy Program, Comprehensive Cancer Center, University of Alabama at Birmingham

Previous Research Appointments

03/96 - 10/96 Associate Professor, Division of Hematology/Oncology, University of Alabama at Birmingham
01/95 - 10/96 Associate Professor of Pathology; Associate Professor of Gynecologic Oncology; Scientist, UAB Arthritis and Musculoskeletal Diseases Center, University of Alabama at Birmingham
07/93 - 10/96 Associate Professor, Department of Medicine; Associate Professor, Department of Microbiology; Scientist, Comprehensive Cancer Center; Scientist, Center for AIDS Research; Scientist, Gregory Fleming Cystic Fibrosis Center, University of Alabama at Birmingham
1992 - 1993 Member, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
1992 - 1993 Curriculum in Genetics, University of North Carolina, Chapel Hill, NC
1991 - 1993 Assistant Professor, Department of Medicine, Division of Pulmonary Diseases, University of North Carolina, Chapel Hill, NC
1989 - 1990 Fellowship, Biotechnology, Navy Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
1985 - 1989 Fellowship, Pulmonary Medicine, Pulmonary Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD.

Academic Degrees

1978 Baccalaureate of Medicine.
1982 Medical Doctor (MD)
2002 Ph.D.